Q-omics provides the consensus-scored KCNE4 profile across patient tissues and cancer cell-line models. KCNE4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCNE4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, KCNE4 RNA expression shows 22,200 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, KIRC, and BRCA as cancer lineages where KCNE4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNE4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNE4 survival associations across molecular data types. KCNE4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNE4 RNA expression–survival associations across cancer types. High KCNE4 expression shows unfavorable associations in KIRP, LGG, MESO and COAD, but favorable associations in UVM and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCNE4 RNA expression.
This table summarizes KCNE4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNE4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNE4 shows lower tumor expression in BLCA and KICH and higher tumor expression in KIRC, HNSC, BRCA and LUAD. The KIRC box plot shows higher KCNE4 RNA expression in tumor versus normal tissue (log2 FC = +1.932, t-test p < 0.001).
This table shows molecular features associated with KCNE4 in patient tissues and cancer cell lines. In patient samples, KCNE4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNE4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
